Impact of Remnant Cholesterol on Cardiovascular Risk in Diabetes.

IF 5.2 2区 医学 Q1 ENDOCRINOLOGY & METABOLISM Current Diabetes Reports Pub Date : 2024-12-01 Epub Date: 2024-10-02 DOI:10.1007/s11892-024-01555-1
Daniel Elías-López, Benjamin Nilsson Wadström, Signe Vedel-Krogh, Camilla Jannie Kobylecki, Børge Grønne Nordestgaard
{"title":"Impact of Remnant Cholesterol on Cardiovascular Risk in Diabetes.","authors":"Daniel Elías-López, Benjamin Nilsson Wadström, Signe Vedel-Krogh, Camilla Jannie Kobylecki, Børge Grønne Nordestgaard","doi":"10.1007/s11892-024-01555-1","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose of review: </strong>Individuals with diabetes face increased risk of atherosclerotic cardiovascular disease (ASCVD), in part due to hyperlipidemia. Even after LDL cholesterol-lowering, residual ASCVD risk persists, part of which may be attributed to elevated remnant cholesterol. We describe the impact of elevated remnant cholesterol on ASCVD risk in diabetes.</p><p><strong>Recent findings: </strong>Preclinical, observational, and Mendelian randomization studies robustly suggest that elevated remnant cholesterol causally increases risk of ASCVD, suggesting remnant cholesterol could be a treatment target. However, the results of recent clinical trials of omega-3 fatty acids and fibrates, which lower levels of remnant cholesterol in individuals with diabetes, are conflicting in terms of ASCVD prevention. This is likely partly due to neutral effects of these drugs on the total level of apolipoprotein B(apoB)-containing lipoproteins. Elevated remnant cholesterol remains a likely cause of ASCVD in diabetes. Remnant cholesterol-lowering therapies should also lower apoB levels to reduce risk of ASCVD.</p>","PeriodicalId":10898,"journal":{"name":"Current Diabetes Reports","volume":null,"pages":null},"PeriodicalIF":5.2000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Diabetes Reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11892-024-01555-1","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/10/2 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose of review: Individuals with diabetes face increased risk of atherosclerotic cardiovascular disease (ASCVD), in part due to hyperlipidemia. Even after LDL cholesterol-lowering, residual ASCVD risk persists, part of which may be attributed to elevated remnant cholesterol. We describe the impact of elevated remnant cholesterol on ASCVD risk in diabetes.

Recent findings: Preclinical, observational, and Mendelian randomization studies robustly suggest that elevated remnant cholesterol causally increases risk of ASCVD, suggesting remnant cholesterol could be a treatment target. However, the results of recent clinical trials of omega-3 fatty acids and fibrates, which lower levels of remnant cholesterol in individuals with diabetes, are conflicting in terms of ASCVD prevention. This is likely partly due to neutral effects of these drugs on the total level of apolipoprotein B(apoB)-containing lipoproteins. Elevated remnant cholesterol remains a likely cause of ASCVD in diabetes. Remnant cholesterol-lowering therapies should also lower apoB levels to reduce risk of ASCVD.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
残余胆固醇对糖尿病患者心血管风险的影响
综述的目的:糖尿病患者罹患动脉粥样硬化性心血管疾病(ASCVD)的风险增加,部分原因在于高脂血症。即使在降低低密度脂蛋白胆固醇后,残余的 ASCVD 风险依然存在,其中部分原因可能是残余胆固醇升高。我们描述了残余胆固醇升高对糖尿病患者 ASCVD 风险的影响:临床前研究、观察性研究和孟德尔随机研究均有力地表明,残余胆固醇升高会增加 ASCVD 风险,这表明残余胆固醇可作为治疗目标。然而,最近关于降低糖尿病患者残余胆固醇水平的欧米伽-3 脂肪酸和纤维酸盐的临床试验结果在预防 ASCVD 方面却相互矛盾。部分原因可能是这些药物对含载脂蛋白 B(apoB)脂蛋白总水平的影响是中性的。残余胆固醇升高仍可能是糖尿病患者发生 ASCVD 的原因之一。降低残余胆固醇的疗法也应降低载脂蛋白B的水平,以降低ASCVD的风险。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
9.80
自引率
0.00%
发文量
52
审稿时长
6-12 weeks
期刊介绍: The goal of this journal is to publish cutting-edge reviews on subjects pertinent to all aspects of diabetes epidemiology, pathophysiology, and management. We aim to provide incisive, insightful, and balanced contributions from leading experts in each relevant domain that will be of immediate interest to a wide readership of clinicians, basic scientists, and translational investigators. We accomplish this aim by appointing major authorities to serve as Section Editors in key subject areas across the discipline. Section Editors select topics to be reviewed by leading experts who emphasize recent developments and highlight important papers published over the past year on their topics, in a crisp and readable format. We also provide commentaries from well-known figures in the field, and an Editorial Board of internationally diverse members suggests topics of special interest to their country/region and ensures that topics are current and include emerging research.
期刊最新文献
Comparative Effects of GLP-1 Agonists, Sleeve Gastrectomy and Roux-en-Y Gastric Bypass on Diabetes Mellitus Outcomes. Technology-Based Interventions to Promote Diabetes Self-Management Behaviors for Persons Newly Diagnosed with Type 2 Diabetes: A Scoping Review. Impact of Remnant Cholesterol on Cardiovascular Risk in Diabetes. Normal Weight Central Obesity and its Impact on Type 2 Diabetes Mellitus. Napping and Obesity in Adults - What do we Know?
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1